The Benzodiazepine Agent Tapering Trial in Japan

The Benzodiazepine Agent Tapering Trial in Japan - BAT trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017765

Enrollment

Registered

2015-06-08

Start date

2015-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mental disease

Interventions

Educational intervention about benzodiazepine by using a text

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient who are commuting to daycare Agreement of patients Outpatient taking two or more medications benzodiazepine receptor agonist during more than three months

Exclusion criteria

Exclusion criteria: A diagnosis of epilepsy, substance use disorder,Intellectual disability, personality disorder,recognition dysfunction Inappropriate patients judged by doctor

Design outcomes

Primary

Measure	Time frame
benzodiazepine dose per day	—

Countries

Japan

Contacts

Public ContactKeiko Hara

National Center of Neurology and Psychiatry Pharmacy

yakuzai4@ncnp.go.jp042-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026